GLP-1 Receptor Agonists and Breast Cancer: Promising Signals, Pressing Questions
- March 16, 2026
Study: Engineered Immune Cells and Targeted Treatments May Slow the Spread of Triple-Negative Breast Cancer
Breakthrough DNA Repair Inhibitor Advances Rapidly Toward Clinic: Artios’ ART6043 Earns FDA Fast Track Status for Resistant Breast Cancer
Bristol Myers Squibb Reports Positive Phase 3 Data for Mezigdomide-Based Oral Regimen in Relapsed or Refractory Multiple Myeloma
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
Saturday, March 21st at 1pm EDT
March is Neuromyelitis Optica (NMO) Awareness Month!
NMO is a rare autoimmune disease that affects the optic nerves and spinal cord, often causing vision loss, pain, and mobility changes. Many people have never heard of it, but awareness can lead to earlier diagnosis, better support and more research.
This month, take a moment to learn, share, and support those living with NMO. Every conversation helps shine a light on rare disease!
#NMOAwareness #NeuromyelitisOptica #nmo #patient Worthy
Study: Engineered Immune Cells and Targeted Treatments May Slow the Spread of Triple-Negative Breast Cancer bit.ly/40q55X8 Read now at PatientWorthy.com
#PatientWorthy #breastcancer #Triple-NegativeBreastCancer
